上海萊士(002252.SZ):控股股東萊士中國被動減持2.89%股份
格隆匯8月28日丨上海萊士(002252.SZ)公佈,控股股東萊士中國原質押給四川信託的7379.17萬股、華鑫信託的1.2129億股的公司股票因逾期還款而構成違約。鑑於前述情況,四川信託和華鑫信託均向上海金融法院申請強制執行,對上述質押的約1.9508億股公司股票進行處置。
根據中國證券登記結算有限責任公司查詢的數據,上述約1.9508億股公司股票已於2020年8月27在中國證券登記結算有限責任公司完成司法過户手續,以抵償相應的債務,萊士中國因此被動減持公司股票約1.9508億股(佔公司總股本的2.89%)。截至目前,萊士中國尚未收到法院有關上述股票被動減持過户的執行裁定書。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.